SCHEMBL31655833

SCHEMBL31655833

C#Cc1cccc2nc(Cn3nc(-c4ccc(O)cc4)c4c(N)ncnc43)n(Cc3ccc(Cl)cc3)c(=O)c12

nearest known ligand 0.71

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 19/20 0.71
▸ PIK3CG P48736 15/20 0.71
▸ PIK3R1 P27986 7/20 0.71
▸ PIK3CA P42336 6/20 0.51
▸ PIK3CB P42338 5/20 0.51
▸ ABL1 P00519 1/20 0.50
▸ SRC P12931 1/20 0.50
▸ MTOR P42345 1/20 0.50
▸ PRKDC P78527 1/20 0.50
▸ MEN1 O00255 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11474 1.00 PIK3CD (0.71) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL12116 0.94 PIK3CD (0.73) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL31655772 0.94 PIK3CD (0.73) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL11397 0.93 PIK3CD (0.71) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL31655822 0.93 PIK3CD (0.71) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL14696 0.93 PIK3CD (0.68) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL11927932 0.93 PIK3CD (0.68) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL31655825 0.93 PIK3CD (0.68) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL31655781 0.93 PIK3CD (0.72) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL11940 0.93 PIK3CD (0.72) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12350302-B2 Dosing regime and formulations for type B adenoviruses Akamis Bio Limited (GB) 2025-07-08 — — US disclosed
Send feedback